Shopping Cart (0)
My Account

 Shopping Cart
Conferences | Training Courses | Market Reports | Managed Events | Past Conferences | Update Me
SELECTBIO Conferences Organ-on-a-Chip and 3D-Culture: Companies, Technologies and Approaches
Conferences  \  Organ-on-a-Chip World Congress & 3D-Culture 2017  \  Organ-on-a-Chip and 3D-Culture: Companies, Technologies and Approaches  \  Agenda  \  Terry Riss
RegisterLogin

Terry Riss's Biography


Terry Riss, Senior Product Manager, Cell Health, Promega Corporation

Dr. Terry Riss started the Cell Biology program at Promega Corporation in 1990 and held several R&D and Project Management positions since. Dr. Riss managed development of cell viability, cytotoxicity, apoptosis, and protease assay systems and lead efforts to identify and promote multiplexing of cell-based assays to determine the mechanism of cell death. Dr. Riss now serves as Senior Product Manager, Cell Health involved in outreach educational training activities including validating assay systems applied to 3D cell culture models. Dr. Riss also serves as an editor of the In Vitro Cell-Based Assays section of the Assay Guidance Manual hosted by The National Center for Advancing Translational Sciences (NCATS) at the NIH.

Terry Riss Image

Real-Time Assays to Monitor Cell Health in 3D Cultures (What You Might be Missing with Endpoint Assays)

Tuesday, 11 July 2017 at 11:30

Add to Calendar ▼2017-07-11 11:30:002017-07-11 12:30:00Europe/LondonReal-Time Assays to Monitor Cell Health in 3D Cultures (What You Might be Missing with Endpoint Assays)SELECTBIOenquiries@selectbiosciences.com

Recording data from the same sample of cells at different incubation times during a treatment protocol provides many advantages compared to using endpoint assays that kill cells and result in only a single measurement. In addition to eliminating error from pipetting into replicate assay plates to measure different endpoints or the same parameter at different times, “real time” assay chemistries that do not kill cells enable many opportunities to use the remaining live cell population for multiplexing with other assay chemistries. We will describe example real time assays applied to 3D cultures to measure cell health parameters (e.g. live cells, dead cells, apoptosis, metabolites) and provide recommendations for how to overcome challenges applying “off the shelf” assays to 3D culture models.

Add to Calendar ▼2017-07-10 00:00:002017-07-11 00:00:00Europe/LondonOrgan-on-a-Chip and 3D-Culture: Companies, Technologies and ApproachesSELECTBIOenquiries@selectbiosciences.com


Corporate Sponsors